Related Experiment Video
Updated: May 9, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
ß-blocker timolol prevents arrhythmogenic Ca²⁺ release and normalizes Ca²⁺ and Zn²⁺ dyshomeostasis in hyperglycemic
Erkan Tuncay1, Esma N Okatan, Guy Vassort
1Department of Biophysics, Faculty of Medicine, Ankara University, Ankara, Turkey.
Abstract:
Defective cardiac mechanical activity in diabetes results from alterations in intracellular Ca(2+) handling, in part, due to increased oxidative stress. Beta-blockers demonstrate marked beneficial effects in heart dysfunction with scavenging free radicals and/or acting as an antioxidant. The aim of this study was to address how β-blocker timolol-treatment of diabetic rats exerts cardioprotection. Timolol-treatment (12-week), one-week following diabetes induction, prevented diabetes-induced depressed left ventricular basal contractile activity, prolonged cellular electrical activity, and attenuated the increase in isolated-cardiomyocyte size without hyperglycemic effect. Both in vivo and in vitro timolol-treatment of diabetic cardiomyocytes prevented the altered kinetic parameters of Ca(2+) transients and reduced Ca(2+) loading of sarcoplasmic reticulum (SR), basal intracellular free Ca(2+) and Zn(2+) ([Ca(2+)]i and [Zn(2+)]i), and spatio-temporal properties of the Ca(2+) sparks, significantly. Timolol also antagonized hyperphosphorylation of cardiac ryanodine receptor (RyR2), and significantly restored depleted protein levels of both RyR2 and calstabin2. Western blot analysis demonstrated that timolol-treatment also significantly normalized depressed levels of some [Ca(2+)]i-handling regulators, such as Na(+)/Ca(2+) exchanger (NCX) and phospho-phospholamban (pPLN) to PLN ratio. Incubation of diabetic cardiomyocytes with 4-mM glutathione exerted similar beneficial effects on RyR2-macromolecular complex and basal levels of both [Ca(2+)]i and [Zn(2+)]i, increased intracellular Zn(2+) hyperphosphorylated RyR2 in a concentration-dependent manner. Timolol also led to a balanced oxidant/antioxidant level in both heart and circulation and prevented altered cellular redox state of the heart. We thus report, for the first time, that the preventing effect of timolol, directly targeting heart, seems to be associated with a normalization of macromolecular complex of RyR2 and some Ca(2+) handling regulators, and prevention of Ca(2+) leak, and thereby normalization of both [Ca(2+)]i and [Zn(2+)]i homeostasis in diabetic rat heart, at least in part by controlling the cellular redox status of hyperglycemic cardiomyocytes.
Insights
Beta-blocker timolol protects diabetic rat hearts by normalizing calcium handling and reducing oxidative stress. This treatment improves cardiac function and cellular electrical activity, preventing diabetic heart dysfunction.
Area of Science:
- Cardiovascular Science
- Diabetology
- Pharmacology
Background:
- Diabetes mellitus causes defective cardiac mechanical activity due to impaired intracellular calcium (Ca2+) handling and increased oxidative stress.
- Beta-blockers, like timolol, show cardioprotective effects by scavenging free radicals and acting as antioxidants.
Purpose of the Study:
- To investigate the cardioprotective mechanisms of beta-blocker timolol in diabetic rats.
- To elucidate how timolol treatment normalizes intracellular Ca2+ handling and redox status in the diabetic heart.
Main Methods:
- Diabetic rats were treated with timolol for 12 weeks.
- Cardiac function, cardiomyocyte electrical activity, and Ca2+ handling (including Ca2+ transients and sparks) were assessed.
- Protein levels of key Ca2+ handling regulators (RyR2, calstabin2, NCX, pPLN/PLN) and cellular redox status were analyzed via Western blot.
Main Results:
- Timolol treatment prevented diabetes-induced depression in left ventricular contractility and attenuated cardiomyocyte hypertrophy.
- Timolol normalized Ca2+ transient kinetics, reduced sarcoplasmic reticulum Ca2+ loading, and corrected basal intracellular Ca2+ and Zn2+ ([Ca2+]i and [Zn2+]i) levels.
- Treatment antagonized ryanodine receptor 2 (RyR2) hyperphosphorylation, restored RyR2 and calstabin2 levels, and normalized NCX and pPLN/PLN ratios.
- Timolol balanced oxidant/antioxidant levels, preventing altered cellular redox state in the diabetic heart.
Conclusions:
- Timolol exerts cardioprotection in diabetic rats by normalizing the RyR2 macromolecular complex and Ca2+ handling regulators.
- The protective effect is linked to preventing Ca2+ leak and restoring [Ca2+]i and [Zn2+]i homeostasis, partly via controlling cellular redox status.
- Timolol offers a potential therapeutic strategy for diabetic cardiomyopathy by addressing both Ca2+ dysregulation and oxidative stress.
More Related Videos
Related Concept Videos
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: β-Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Action of Calcium Channel Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antihypertensive Drugs: Action of β1 Blockers

